JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Scope & Guideline
Unveiling the Mechanisms of Drug Action
Introduction
Aims and Scopes
- Population Pharmacokinetics and Pharmacodynamics:
The journal emphasizes studies that utilize population pharmacokinetic and pharmacodynamic models to analyze drug behavior in diverse patient populations. This area is crucial for optimizing dosing regimens and understanding variability in drug responses. - Quantitative Systems Pharmacology (QSP):
QSP is a core focus, integrating biological systems modeling with pharmacokinetic and pharmacodynamic principles. This approach aids in predicting drug effects and interactions within complex biological systems, facilitating better drug development strategies. - Mechanistic and Semi-Mechanistic Modeling:
Research that develops mechanistic or semi-mechanistic models to describe drug action and interactions at various biological levels is prevalent. These models help elucidate the underlying biological processes affecting drug behavior. - Innovative Computational Techniques:
The journal showcases the application of advanced computational techniques, including machine learning and artificial intelligence, to pharmacokinetic and pharmacodynamic modeling, aiming to improve predictive accuracy and model efficiency. - Clinical Applications and Translational Research:
There is a strong emphasis on studies that bridge the gap between theoretical modeling and clinical application, particularly in areas such as oncology, rare diseases, and chronic conditions, enhancing the relevance of pharmacometric research to real-world clinical scenarios.
Trending and Emerging
- Integration of Machine Learning in Pharmacometrics:
There is a growing trend in utilizing machine learning techniques to enhance pharmacometric modeling. This includes applications in model selection, optimization, and predictive analytics, which are increasingly recognized for their potential to improve the robustness and efficiency of pharmacokinetic/pharmacodynamic analyses. - Focus on Rare Diseases and Pediatric Populations:
Research addressing pharmacokinetics and pharmacodynamics in rare diseases and pediatric populations is gaining momentum. This reflects a broader recognition of the need for tailored therapeutic strategies in these vulnerable groups. - Virtual Patient Models and Simulations:
The use of virtual patient models and simulations to predict drug responses and optimize treatment regimens is on the rise. These models allow for the exploration of various dosing scenarios and patient characteristics, enhancing translational research efforts. - Mechanistic Insights into Drug Action:
There is an increasing emphasis on studies that provide mechanistic insights into drug action and interactions, particularly through the development of semi-mechanistic and mechanistic models. This trend supports a deeper understanding of how drugs exert their effects at the biological level. - Emphasis on Quantitative Systems Pharmacology (QSP):
QSP is becoming a dominant theme, with a focus on integrating biological data with pharmacometric models to enhance the predictive capabilities of drug development processes. This approach is critical for improving the translation of preclinical findings to clinical outcomes.
Declining or Waning
- Traditional Compartmental Models:
There has been a noticeable decrease in the publication of studies exclusively relying on traditional compartmental models. As more sophisticated modeling approaches, such as physiologically-based pharmacokinetic (PBPK) models, gain traction, the relevance of simpler compartmental methods appears to be waning. - Basic Pharmacokinetic Studies:
Research focused solely on basic pharmacokinetic parameters without integrating pharmacodynamic aspects or clinical implications has decreased. The journal is increasingly favoring studies that combine pharmacokinetics with pharmacodynamics to provide a more comprehensive analysis. - Single-Agent Drug Studies:
The focus on studies examining the pharmacokinetics and pharmacodynamics of single-agent drugs is declining, as there is a growing interest in combination therapies and their complex interactions, particularly in oncology and chronic disease treatment. - Static Modeling Approaches:
Static models that do not account for variability or dynamic changes in drug effects over time are being replaced by more dynamic and flexible modeling approaches. This trend indicates a shift towards methods that better capture the complexities of drug action in real-world scenarios.
Similar Journals
DRUG METABOLISM AND DISPOSITION
Innovating Insights in Drug DispositionDrug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.
DRUG DEVELOPMENT RESEARCH
Driving the evolution of medicine with impactful research.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.
BMC Pharmacology & Toxicology
Unveiling the complexities of drug action and safety.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
Drug Design Development and Therapy
Elevating Drug Discovery with High-Impact ResearchDrug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.
CLINICAL PHARMACOLOGY & THERAPEUTICS
Transforming research into practice in clinical pharmacology.CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.
ANTI-CANCER DRUGS
Pioneering Discoveries in Oncology PharmacologyANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Delivering High-Impact Research for Healthcare ProfessionalsBASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Innovative Insights in Medicine and Pharmaceutical ScienceBIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.
JOURNAL OF PHARMACY AND PHARMACOLOGY
Advancing pharmaceutical knowledge for a healthier tomorrow.Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.
JOURNAL OF CLINICAL PHARMACOLOGY
Advancing the Science of Drug TherapyWelcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.